Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know-Reference-Cited by-同舟云学术

Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know

Published:2022-03-09 Issue:8 Volume:55 Page:944-959
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Barritt A. Sidney¹^ORCID,Marshman Emma²,Noureddin Mazen³^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology, UNC Liver Center University of North Carolina at Chapel Hill Chapel Hill NC USA

2. Spirit Medical Communications Manchester UK

3. Department of Medicine Cedars‐Sinai Medical Center Los Angeles CA USA

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16794

Reference109 articles.

1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

2. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

3. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease

4. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study

5. NAFLD : Reporting Histologic Findings in Clinical Practice

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial;Diseases;2024-08-17

2. Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study;Diabetologia;2024-08-06

3. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis;Clinical Gastroenterology and Hepatology;2024-08

4. What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives;International Journal of Molecular Sciences;2024-07-15

5. Update on Newly Federal Drug Administration-Approved Drug, Resmetirom: A Practical Perspective;American Journal of Gastroenterology;2024-06-28